title: Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open-label study.
authors.affiliation: Sheba Medical Center, Tel Hashomer, Israel.
authors.forename: Yair
authors.initials: Y
authors.lastname: Levy
authors.forename: Howard
authors.initials: H
authors.lastname: Amital
authors.forename: Pnina
authors.initials: P
authors.lastname: Langevitz
authors.forename: Francesca
authors.initials: F
authors.lastname: Nacci
authors.forename: Anna
authors.initials: A
authors.lastname: Righi
authors.forename: Letizia
authors.initials: L
authors.lastname: Conforti
authors.forename: Sergio
authors.initials: S
authors.lastname: Generini
authors.forename: Marco
authors.initials: M
authors.lastname: Matucci Cerinic
authors.forename: Yehuda
authors.initials: Y
authors.lastname: Shoenfeld
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D005355:Fibrosis; D006801:Humans; D016756:Immunoglobulins, Intravenous; D008297:Male; D008875:Middle Aged; D012595:Scleroderma, Systemic / Q000188:drug therapy* / Q000473:pathology*; D012867:Skin / Q000473:pathology*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D016756:Immunoglobulins, Intravenous